N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Phase 2 N=25 Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Gastroparesis
Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
N/A N=146 Aspiration of Residual Gastric Contents
Infant, Premature · Nutrition, Enteral
Primary: Enteral Intake on Day of Life 7 — 27.5; 22.6 mL/kg per day — p=0.27
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
Phase 2 N=36 Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
N/A N=32 Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
Gastroparesis
Primary: Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index. — 6.8; 10.1 units on a scale
N/A N=22 Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis
Gastric Stasis
Primary: Percentage of Slow Wave Entrainment — 72; 70; 84; 78 percentage of slow waves entrainment
Phase 4 N=72 Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Pregnancy · Cesarean Section · Aspiration
Primary: Change in Gastric Volume (mL) — -1; -2; 0; 1 Milliliters — p=.001
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 4 N=20 Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying
Obesity
Primary: Gastric Emptying Half-time (T 1/2) of Solids — 187; 86 minutes — p=<.001
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
Phase 2 N=20 A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
Gastroparesis · Diabetes Mellitus
Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002
N/A N=64 Gastrointestinal Activation Post-elective CS (Cesarean Section) :A Comparison of Paula Method to Standard Care
Bowel Dysfunction
Primary: Time to the Resumption of Bowel Functioning as Assessed by Flatus Passage — 24.1; 39.1 hours — p=<0.05
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
Early Phase 1 N=14 Pioglitazone for Idiopathic Gastroparesis
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
N/A N=20 Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility
Gastroparesis · Dyspepsia
Primary: Frequency of Contractions at Baseline — 20; 24.6; 23.7 stomach contractions/minute
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
N/A N=592 Residual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
Diabetes Mellitus
Primary: Residual Gastric Volume — 22.1; 33.1; 40.2 mL — p=<0.05
N/A N=449 Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
N/A N=10 Does Adding Milk to Tea Delay Gastric Emptying?
Gastric Emptying
Primary: Tmax — 38; 30 minutes
Phase 2 N=110 Metoclopramide Versus Placebo for GJ Placement
Radiation Exposure · Enteral Nutrition
Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes
Phase 2 N=92 Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
Phase 2 N=96 Buspirone for Early Satiety and Symptoms of Gastroparesis
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
Phase 2 N=14 Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma
Morbid Obesity
Primary: Primary Outcome: Change in Body Weight — 9.6 kg
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months